Publikationen, an denen er mitarbeitet María Ujué Latasa Sada (26)

2024

  1. Caspases compromise SLU7 and UPF1 stability and NMD activity during hepatocarcinogenesis

    JHEP Reports, Vol. 6, Núm. 8

  2. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

    Gut

  3. New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 5

  4. Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)

    Clinical science (London, England : 1979), Vol. 138, Núm. 20, pp. 1265-1284

2023

  1. Comprehensive analysis of epigenetic and epitranscriptomic genes’ expression in human NAFLD

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 901-924

  2. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

2022

  1. Activation of the unfolded protein response (Upr) is associated with cholangiocellular injury, fibrosis and carcinogenesis in an experimental model of fibropolycystic liver disease

    Cancers, Vol. 14, Núm. 1

  2. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

2021

  1. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma

    Hepatology, Vol. 73, Núm. 6, pp. 2380-2396

  2. Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: Dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis

    Gut, Vol. 70, Núm. 2, pp. 388-400

  3. Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge

    Oncogene, Vol. 40, Núm. 23, pp. 4033-4049

  4. The splicing regulator SLU7 is required to preserve DNMT1 protein stability and DNA methylation

    Nucleic Acids Research, Vol. 49, Núm. 15, pp. 8592-8609

2020

  1. Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: A machine-learning approach

    Cancers, Vol. 12, Núm. 6, pp. 1-30

2019

  1. Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma

    Hepatology, Vol. 69, Núm. 2, pp. 587-603

  2. Splicing events in the control of genome integrity: Role of SLU7 and truncated SRSF3 proteins

    Nucleic Acids Research, Vol. 47, Núm. 7, pp. 3450-3466

  3. The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis

    Hepatology, Vol. 69, Núm. 4, pp. 1632-1647

2018

  1. Bile acids, FGF15/19 and liver regeneration: From mechanisms to clinical applications

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1326-1334

2017

  1. Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice

    Cell Death and Disease, Vol. 8, Núm. 10

  2. Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: Development of an FGF19-based chimeric molecule to promote fatty liver regeneration

    Gut, Vol. 66, Núm. 10, pp. 1818-1828

2016

  1. Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression

    Oncogene, Vol. 35, Núm. 36, pp. 4719-4729